IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models

Shao Wei Lu, Hong Chin Pan, Yu Hsiang Hsu, Kung Chao Chang, Li Wha Wu, Wei Yu Chen, Ming Shi Chang

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


Pancreatic ductal adenocarcinoma (PDAC) and cancer-associated cachexia (CAC) are multifactorial and characterized by dysregulated inflammatory networks. Whether the proinflammatory cytokine IL-20 is involved in the complex networks of PDAC and CAC remains unclear. Here, we report that elevated IL-20 levels in tumor tissue correlate with poor overall survival in 72 patients with PDAC. In vivo, we establish a transgenic mouse model (KPC) and an orthotopic PDAC model and examine the therapeutic efficacy of an anti-IL-20 monoclonal antibody (7E). Targeting IL-20 not only prolongs survival and attenuates PD-L1 expression in both murine models but also inhibits tumor growth and mitigates M2-like polarization in the orthotopic PDAC model. Combination treatment with 7E and an anti-PD-1 antibody shows better efficacy in inhibiting tumor growth than either treatment alone in the orthotopic PDAC model. Finally, 7E mitigates cachexic symptoms in CAC models. Together, we conclude IL-20 is a critical mediator in PDAC progression.

Original languageEnglish
Article number4611
JournalNature communications
Issue number1
Publication statusPublished - 2020 Dec 1

All Science Journal Classification (ASJC) codes

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)


Dive into the research topics of 'IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models'. Together they form a unique fingerprint.

Cite this